Skip to main content
SpringerLink
Log in

Wechsel von Originalpräparaten auf Generika

Ein Fallbeispiel mit Oxcarbazepin

Change from original preparations to generics

A case example with oxcarbazepine

  • Briefe an die Herausgeber
  • Published:
Der Nervenarzt Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Abb. 1

Literatur

  1. Kramer G, Elger CE, Denning D, Neubauer BA (2008) Ad-hoc-Kommision der Deutschen Gesellschaft für Epileptologie, Aut-idem-Ankreuzen: bei Antiepileptika wichtiger denn je! Akt Neurol 35:2

    Article  Google Scholar 

  2. Bazil CW (2009) Epilepsy: Generic substitution: are antiepileptic drugs different? Nat Rev Neurol 5:587–588

    Article  CAS  PubMed  Google Scholar 

  3. Andermann F, Duh MS, Gosselin A, Paradis PE (2007) Compulsory generic switching of antiepileptic drugs: high switchback rates to branded compounds compared with other drug classes. Epilepsia 48:464–469

    Article  CAS  PubMed  Google Scholar 

  4. LeLorier J, Duh MS, Paradis PE et al (2008) Clinical consequences of generic substitution of lamotrigine for patients with epilepsy. Neurology 70:2179–2186

    Article  CAS  PubMed  Google Scholar 

  5. Kramer G, Steinhoff BJ, Feucht M et al (2007) Experience with generic drugs in epilepsy patients: an electronic survey of members of the German, Austrian and Swiss branches of the ILAE. Epilepsia 48:609–611

    Article  PubMed  Google Scholar 

  6. Steinhoff BJ, Runge U, Witte OW et al (2009) Substitution of anticonvulsant drugs. Ther Clin Risk Manag 5:449–457

    Article  CAS  PubMed  Google Scholar 

  7. Gidal BE (2009) Bioequivalence of antiepileptic drugs: how close is close enough? Curr Neurol Neurosci Rep 9:333–337

    Article  PubMed  Google Scholar 

  8. Perucca E, Albani F, Capovilla G et al (2006) Recommendations of the Italian League against Epilepsy working group on generic products of antiepileptic drugs. Epilepsia 47(Suppl 5):16–20

    Article  PubMed  Google Scholar 

  9. Kramer G, Denning D, Schmidt D et al (2005) Ad-hoc-Kommision der Deutschen Gesellschaft für Epileptologie, Generika in der Epilepsietherapie: Was ist zu beachten? Akt Neurol 32:4

    Google Scholar 

  10. Shaw SJ, Krauss GL (2008) Generic antiepileptic drugs. Curr Treat Options Neurol 10:260–268

    Article  PubMed  Google Scholar 

  11. Wilner AN (2004) Therapeutic equivalency of generic antiepileptic drugs: results of a survey. Epilepsy Behav 5:995–998

    Article  PubMed  Google Scholar 

  12. Duh MS, Cahill KE, Paradis PE et al (2009) The economic implications of generic substitution of antiepileptic drugs: a review of recent evidence. Expert Opin Pharmacother 10:2317–2328

    Article  CAS  PubMed  Google Scholar 

  13. Duh MS, Paradis PE, Latremouille-Viau D et al (2009) The risks and costs of multiple-generic substitution of topiramate. Neurology 72:2122–2129

    Article  CAS  PubMed  Google Scholar 

  14. Zachry WM 3rd, Doan QD, Clewell JD, Smith BJ (2009) Case-control analysis of ambulance, emergency room, or inpatient hospital events for epilepsy and antiepileptic drug formulation changes. Epilepsia 50:493–500

    Article  CAS  PubMed  Google Scholar 

  15. Aut-idem Daten (2008) Waldems-Esch. Insight Health GmbH & Co KG

Download references

Interessenkonflikt

Der korrespondierende Autor weist auf folgende Beziehungen hin: G. Hagemann erhielt Referentenhonorare von Eisai GmbH, Desitin-Pharma und UCB Germany und erhielt Unterstützung für Kongressreisen von Schwarz-Pharma GmbH, Eisai GmbH und Cyberonics. J. Zinke erhielt Unterstützung für Kongressreisen und Seminarteilnahmen von UCB Germany, Janssen-Cilag und Eisai GmbH.

Author information

Authors and Affiliations

  1. Hans Berger Klinik für Neurologie, Friedrich-Schiller-Universität, Jena, Deutschland

    G. Hagemann, J. Zinke, M. Fuchs & O.W. Witte

Authors
  1. G. Hagemann
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. J. Zinke
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. M. Fuchs
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. O.W. Witte
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to G. Hagemann.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Hagemann, G., Zinke, J., Fuchs, M. et al. Wechsel von Originalpräparaten auf Generika. Nervenarzt 81, 1498–1500 (2010). https://doi.org/10.1007/s00115-010-3033-5

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00115-010-3033-5

Search

Navigation